867 related articles for article (PubMed ID: 34850173)
1. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
[TBL] [Abstract][Full Text] [Related]
2. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
3. Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Koya D; Anker SD; Ruilope LM; Rossing P; Liu Z; Lee BW; Lee CT; Scott C; Kolkhof P; Lawatscheck R; Wang L; Joseph A; Pitt B;
Am J Nephrol; 2023; 54(9-10):370-378. PubMed ID: 37708857
[TBL] [Abstract][Full Text] [Related]
4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
[TBL] [Abstract][Full Text] [Related]
5. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
6. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
7. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
Ruilope LM; Pitt B; Anker SD; Rossing P; Kovesdy CP; Pecoits-Filho R; Pergola P; Joseph A; Lage A; Mentenich N; Scheerer MF; Bakris GL
Nephrol Dial Transplant; 2023 Feb; 38(2):372-383. PubMed ID: 35451488
[TBL] [Abstract][Full Text] [Related]
8. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
9. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
[TBL] [Abstract][Full Text] [Related]
10. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
[TBL] [Abstract][Full Text] [Related]
11. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
13. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
14. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Rossing P; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Amod A; Marre M; Joseph A; Lage A; Scott C; Bakris GL;
Diabetes Obes Metab; 2022 Jan; 24(1):125-134. PubMed ID: 34580995
[TBL] [Abstract][Full Text] [Related]
16. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
17. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
[TBL] [Abstract][Full Text] [Related]
18. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis.
Pitt B; Agarwal R; Anker SD; Ruilope LM; Rossing P; Ahlers C; Brinker M; Joseph A; Lambelet M; Lawatscheck R; Filippatos GS;
JAMA Netw Open; 2022 Oct; 5(10):e2236123. PubMed ID: 36287567
[TBL] [Abstract][Full Text] [Related]
19. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Nowack C; Schloemer P; Joseph A; Filippatos G;
N Engl J Med; 2020 Dec; 383(23):2219-2229. PubMed ID: 33264825
[TBL] [Abstract][Full Text] [Related]
20. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
Flack JM; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Adler SG; Fried L; Jamerson K; Toto R; Brinker M; Farjat AE; Kolkhof P; Lawatscheck R; Joseph A; Bakris GL;
Kidney Med; 2023 Dec; 5(12):100730. PubMed ID: 38046911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
